Related Experiment Video
Updated: May 30, 2026
08:29
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
[Dementia--distribution and diagnostic criteria]
Magdalena Torbus1, Marek Ksol, Bogdan Mazur
1Oddział Psychiatryczny dla Chorych Somatycznie, SP ZOZ Państwowy Szpital Dla Psychicznie i Nerwowo Chorych Rybniku.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|August 5, 2011
Summary
As populations age, cognitive disorders like dementia become more prevalent. This article details diagnostic criteria for Alzheimer's disease and vascular dementia, aiding specialists in identifying these conditions.
Area of Science:
- Gerontology
- Neurology
- Public Health
Context:
- The global population is aging, leading to an increased prevalence of age-related health issues.
- Cognitive function disorders are becoming a significant concern among the elderly population.
- Dementia, particularly Alzheimer's disease, is a leading cause of cognitive impairment in older adults.
Purpose:
- To outline the diagnostic criteria for dementia in Alzheimer's disease.
- To describe the diagnostic criteria for vascular dementia.
- To briefly mention assessment scales for cognitive function disorders.
Summary:
- This article addresses the growing challenge of cognitive disorders in an aging population.
- It provides a detailed overview of the diagnostic criteria for both Alzheimer's disease-related dementia and vascular dementia.
- The discussion also touches upon scales used to evaluate cognitive impairments.
Impact:
- Aids healthcare professionals in accurately diagnosing dementia subtypes.
- Facilitates better patient management and treatment planning for cognitive decline.
- Contributes to understanding the scope of dementia within the context of population aging.
More Related Videos
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...